Insider Selling: BioMarin Pharmaceutical CEO Sells 3,000 Shares of Stock (BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 3,000 shares of the stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $66.76, for a total value of $200,280.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
BMRN has been the subject of a number of recent research reports. Analysts at Wells Fargo & Co. reiterated a “market perform” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, September 27th. Separately, analysts at Wedbush reiterated a “hold” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, September 20th. They now have a $88.00 price target on the stock. Finally, analysts at William Blair reiterated a “hold” rating on shares of BioMarin Pharmaceutical in a research note to investors on Wednesday, September 18th. They now have a $88.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $72.68.
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 2.48% during mid-day trading on Tuesday, hitting $66.39. 1,318,615 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 1-year low of $36.28 and a 1-year high of $80.67. The stock has a 50-day moving average of $71.47 and a 200-day moving average of $64.86. The company’s market cap is $9.302 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, July 25th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.29) by $0.13. The company had revenue of $136.80 million for the quarter, compared to the consensus estimate of $134.33 million. During the same quarter last year, the company posted ($0.27) earnings per share. BioMarin Pharmaceutical’s revenue was up 10.3% compared to the same quarter last year. On average, analysts predict that BioMarin Pharmaceutical will post $-1.15 earnings per share for the current fiscal year.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.